Don’t Let Recent momentum Confuse Your Outlook on Chimerix Inc. [CMRX]

Chimerix Inc. [CMRX] stock is up 13.26 while the S&P 500 has fallen -0.08% on Friday, 12/04/20. While at the time of this article, CMRX ATR is sitting at 0.23, with the beta value at 1.83. This stock’s volatility for the past week remained at 7.60%, while it was 6.90% for the past 30-day period. CMRX has risen $0.48 from the previous closing price of $3.62 on volume of 1.56 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 7, December 2020, Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox. According to news published on Yahoo Finance, FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021.

Analyst Birdseye View:

The most recent analyst activity for Chimerix Inc. [NASDAQ:CMRX] stock was on February 02, 2018, when it was Initiated with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $10. On August 09, 2016, FBR Capital Reiterated a Mkt perform rating and plunged its price target on this stock from $9 to $8. On February 23, 2016, FBR Capital Reiterated a Mkt perform rating and decreased its price target from $14 to $10. On February 23, 2016, Morgan Stanley Downgrade an Underweight rating. On February 23, 2016, Barclays Downgrade an Equal weight rating and boosted its amount target on this stock to $6. On February 22, 2016, Citigroup Downgrade a Neutral rating. On December 29, 2015, JP Morgan Downgrade a Neutral rating and improved its amount target to $15.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.19 and a peak of $4.06. Right now, according to Wall Street analyst the average 12-month amount target is $6.67. At the most recent market close, shares of Chimerix Inc. [NASDAQ:CMRX] were valued at $4.10.


Chimerix Inc. [NASDAQ:CMRX] most recently reported quarterly sales of 1.61 billion, which represented growth of -20.00%. This publicly-traded organization’s revenue is $291,140 per employee, while its income is -$2,618,047 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -72.61, -78.30, -31.37 and -78.25 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 0.77 and the whole liability to whole assets at 0.71. It shows enduring liability to the whole principal at 0.18 and enduring liability to assets at 0.00 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.48 points at 1st support level, the second support level is making up to 3.33. But as of 1st resistance point, this stock is sitting at 3.70 and at 3.77 for 2nd resistance point.

Chimerix Inc. [CMRX] reported its earnings at -$0.18 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.17/share signifying the difference of -0.01 and -5.90% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.16 calling estimates for -$0.17/share with the difference of 0.01 depicting the surprise of 5.90%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Chimerix Inc. [NASDAQ:CMRX] is 12.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 12.30. Now if looking for a valuation of this stock’s amount to sales ratio it’s 9.00 and it’s amount to book ratio is 1.14.

Insider Stories

The most recent insider trade was by Jakeman David, Principal Accounting Officer, and it was the sale of 4270.0 shares on Oct 02. Meyer Robert J., the Director, completed a purchase of 3500.0 shares on Aug 19. On Aug 10, DEMSKI MARTHA J, Director, completed a sale of 1584.0 shares.